That is a major concern IF first off anchor is approved and there is no delay. GiA will kill any momo pps rise event. Initially the pps will rise but they will have to do another round of dilution to market anchor. Another reason I am in the buyout camp. This just drags out success much further out!
Generally in Biomed's the stock is valued at potential sales for a drug/pipeline. Not the actual value, good chance of the PPS doubling. Look at CLDX up from 3's to $25 based not on sales/pipeline potential. They are years from actually selling anything. Hope this helps!